Regeneron Pharmaceuticals, Inc. P/E Ratio 2008–2025
Regeneron Pharmaceuticals, Inc. reported 18.56 of price-to-earnings ratio for fiscal 2025. That was 0.7% higher than fiscal 2024. Compared with fiscal 2020, the change was +18.2%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 18.56 | +0.7% |
| FY 2024 | 18.43 | -26.4% |
| FY 2023 | 25.05 | +33.8% |
| FY 2022 | 18.72 | +115.1% |
| FY 2021 | 8.70 | -44.6% |
| FY 2020 | 15.70 | -22.2% |
| FY 2019 | 20.17 | +15.9% |
| FY 2018 | 17.40 | -51.8% |
| FY 2017 | 36.06 | -23.7% |
| FY 2016 | 47.28 | -51.5% |
| FY 2015 | 97.54 | -28.6% |
| FY 2014 | 136.54 | +86.1% |
| FY 2013 | 73.38 | +191.9% |
| FY 2012 | 25.14 | — |
| FY 2011 | — | — |
| FY 2010 | — | — |
| FY 2009 | — | — |
| FY 2008 | — | — |
Source: Regeneron Pharmaceuticals, Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open REGN 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Regeneron Pharmaceuticals, Inc. reported 18.56 of price-to-earnings ratio for fiscal 2025. That was 0.7% higher than fiscal 2024. Compared with fiscal 2020, the change was +18.2%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Regeneron Pharmaceuticals, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeRegeneron Pharmaceuticals, Inc. — frequently asked questions
What is Regeneron Pharmaceuticals, Inc.'s price-to-earnings ratio?
Regeneron Pharmaceuticals, Inc. (REGN) reported price-to-earnings ratio of 18.56 for fiscal year 2025, per its SEC filings.
How has Regeneron Pharmaceuticals, Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2008 and 2025, REGN's price-to-earnings ratio declined at roughly 1.8% per year (compound annual rate), from 25.14 to 18.56.
Where does this data come from?
Figures are computed from Regeneron Pharmaceuticals, Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.
More REGN financial history
Full REGN fundamentals page → · Analyze price-to-earnings ratio with a free tool → · Research guide & leaders → · All 1,500+ companies →